LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Начало・Списък с акции・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Отворен

Сектор Здравеопазване

7.99 6.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.45

Максимум

8.16

Ключови измерители
By Trading Economics
EPS	-0.172
Марж на печалбата	-66.092
Служители	536

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+108.4 upside

Дивиденти
By Dow Jones
Следващи печалби	4.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	41M 990M
Предишно отваряне	1.88
Предишно затваряне	7.99

Настроения в новините

By Acuity

50%

148 / 366 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

6.1 / 7.65 Подкрепа & съпротива

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.10.2024 г., 23:17 ч. UTC

Топ новини

Australian Consumer Confidence Highest Since Early 2023

21.10.2024 г., 20:42 ч. UTC

Печалби

SAP 3Q Revenue, Profit Climb on AI Demand; Outlook Raised

21.10.2024 г., 22:57 ч. UTC

Печалби

Ping An Insurance: Higher Income From Healthcare, Senior-Care Services Supported Results >2318.HK

21.10.2024 г., 22:57 ч. UTC

Печалби

Ping An Insurance 9-Mos Rev CNY861.8B ; Up 8.7% on Year >2318.HK

21.10.2024 г., 22:57 ч. UTC

Печалби

Ping An Insurance 9-Mos Net CNY119.2B; Up 36.1% on Year >2318.HK

21.10.2024 г., 22:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Webjet Looks Like an M&A Target, But Bids Unlikely Soon -- Market Talk

21.10.2024 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Deal Jitters Imperil Stock's Big Rebound -- Barrons.com

21.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

21.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.10.2024 г., 20:32 ч. UTC

Печалби

Nucor: The Earnings of the Raw Materials Segment Are Expected to Increase in 4Q Compared to 3Q >NUE

21.10.2024 г., 20:31 ч. UTC

Печалби

Nucor: Expect Consolidated Net Earnings Attributable to Nucor Stockholders in 4Q to Decrease >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Steel Mills Total Shipments 5.72M Tons >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Average Sales Price Per Ton Down 15% >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q EPS $1.05 >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Sales $7.44B >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Net $249.9M >NUE

21.10.2024 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Glendon Capital Filing Mentions Reuters Article About Glendon Opposition to Verizon Deal

21.10.2024 г., 20:20 ч. UTC

Топ новини

Nvidia Reaches $3.5 Trillion Market Value. It's Right on Apple's Heels. -- Barrons.com

21.10.2024 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Frontier Communications Shareholder Glendon Capital Will Continue to Engage in Talks With Relevant Parties About Sale to Verizon

21.10.2024 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

21.10.2024 г., 20:14 ч. UTC

Топ новини

S&P 500, Dow Slip; Bond Yields Rise -- WSJ

21.10.2024 г., 20:10 ч. UTC

Печалби

SAP Backs 2024 Cloud Revenue EUR17B-EUR17.3B >SAP

21.10.2024 г., 20:10 ч. UTC

Печалби

SAP Raises 2024 Cloud and Software Revenue View to EUR29.5B-EUR29.8B >SAP

21.10.2024 г., 20:08 ч. UTC

Печалби

SAP Sees Exiting 2024 at Headcount Slightly Ahead of Year-End 2023 >SAP

21.10.2024 г., 20:07 ч. UTC

Печалби

SAP 3Q Cloud and Software Revenue EUR7.43B >SAP

21.10.2024 г., 20:07 ч. UTC

Печалби

SAP 3Q Software Licenses Revenue EUR280M>SAP

21.10.2024 г., 20:06 ч. UTC

Печалби

SAP 3Q Adj EPS EUR1.23 >SAP

21.10.2024 г., 20:06 ч. UTC

Печалби

SAP 3Q EPS EUR1.25 >SAP

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

108.4% нагоре

12-месечна прогноза

Среден 15.88 USD 108.4%

Висок 30 USD

Нисък 7 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на BioCryst Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

6.1 / 7.65Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Настроение

By Acuity

148 / 366 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.